Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05904496
Title	A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	BeiGene
Indications	lung non-small cell carcinoma lung small cell carcinoma renal cell carcinoma hepatocellular carcinoma stomach carcinoma nasopharynx carcinoma cervical cancer esophageal carcinoma melanoma transitional cell carcinoma skin squamous cell carcinoma head and neck squamous cell carcinoma triple-receptor negative breast cancer Advanced Solid Tumor Merkel cell carcinoma malignant mesothelioma endometrial carcinoma gastroesophageal adenocarcinoma
Therapies	BGB-30813 BGB-30813 + Tislelizumab
Age Groups:	adult \| senior
Covered Countries	USA \| ESP \| AUS

Filter rows:

Showing 1 to 8 of 8 entries

Facility	Status	City	State	Zip	Country	Details
Hackensack University Medical Center	RECRUITING	Hackensack	New Jersey	07601	United States	Details
Hospital Universitario Vall Dhebron	RECRUITING	Barcelona		08035	Spain	Details
Linear Clinical Research	RECRUITING	Nedlands	Western Australia	6009	Australia	Details
Md Anderson Cancer Center	RECRUITING	Houston	Texas	77030	United States	Details
Monash Health	RECRUITING	Clayton	Victoria	3168	Australia	Details
Next Oncology	RECRUITING	San Antonio	Texas	78229	United States	Details
Peter Maccallum Cancer Centre	RECRUITING	Melbourne	Victoria	3000	Australia	Details
Start Madrid Fundacion Jimenez Diaz	RECRUITING	Madrid		28040	Spain	Details

Showing 1 to 8 of 8 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field